^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCL20 underexpression

    i
    Other names: CCL20, C-C Motif Chemokine Ligand 20, LARC, Small Inducible Cytokine Subfamily A (Cys-Cys), Member 20, Liver And Activation-Regulated Chemokine, Macrophage Inflammatory Protein 3 Alpha, Chemokine (C-C Motif) Ligand 20, Small-Inducible Cytokine A20, C-C Motif Chemokine 20, CC Chemokine LARC, MIP-3-Alpha, MIP-3a, SCYA20, MIP3A, CKb4, ST38, Beta Chemokine Exodus-1, Beta-Chemokine Exodus-1, Exodus-1, Exodus
    Entrez ID:
    6364
    Related biomarkers:
    Expression
    Others
    over2years
    CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition. (PubMed, Int J Biol Sci)
    Using another independent cohort of 348 urothelial carcinoma patients treated with the anti-PD-L1 agent (atezolizumab), we explored the synergistic effect of CCL20 and TGF-β on immunotherapy efficacy...Collectively, we revealed the underlying mechanisms by which CCL20 promotes LUAD progression based on the largest sample size. The synergistic inhibitory effect of CCL20 and TGF-β on immune-checkpoint blockade therapy efficacy provides new views of immunotherapy resistance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CCL20 (C-C Motif Chemokine Ligand 20) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    CCL20 underexpression
    |
    Tecentriq (atezolizumab)